Haemoadsorption During Heart Transplantation

Recruiting now · Not applicable

Conditions studied: Heart Transplantation

In brief

To investigate whether the use of haemoadsorption (HA) on cardiopulmonary bypass during heart transplantation (HTX) has an effect on circulating cytokine levels for the first 120 hours after HTX and induces a decreased inflammatory response, increased anti-inflammatory response or immunosuppressive response. Additionally, the influence of HA on primary graft dysfunction, postoperative cerebral dysfunction, postoperative fluid accumulation, renal dysfunction, duration of mechanical ventilation, length of ICU-stay and 30-day mortality should be investigated

Key facts

Study ID

NCT05270902

Run by

Medical University of Vienna

People needed

40

Starts

2022-09-01

Expected to finish

2026-06-30

Last updated by the study team

2025-05-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients undergoing heart transplantation

You may not qualify if…

• Declined informed consent
• Age < 18 years#
• Receiving antileukocyte drugs
• Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab)
• DCD
• Ex-vivo perfusion

Where it is running

• Divison of Cardiac Thoracic Vascular Anaesthesia and Intensive Care, Medical University of Vienna — Vienna, State of Vienna, Austria (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.